Akebia Therapeutics (AKBA) EBITDA Margin (2017 - 2026)
Akebia Therapeutics (AKBA) recorded EBITDA Margin of -11.69% in Q2 2026, down 34.74 percentage points from 23.06% a year earlier and down 3.53 percentage points from the prior quarter.
Powered by 
Analysis
Akebia Therapeutics (AKBA) EBITDA Margin (2017 - 2026) Analysis & Trends
On a TTM basis, Akebia Therapeutics' EBITDA Margin came in at -6.20% as of Jun 30, 2026, down 16.08 percentage points year-over-year; for FY2025, it came in at 10.49%, up 18.58 percentage points from FY2024.
- Annual EBITDA Margin has a five-year change of +126.94 percentage points (FY2020 to FY2025).
- Across earlier years, EBITDA Margin came in at -8.10% in FY2024 (-3.66 pp), -4.43% in FY2023 (+10.30 pp), -14.73% in FY2022 (+92.30 pp) and -107.03% in FY2021 (+9.43 pp).
- Quarterly EBITDA Margin has ranged from -96.89% in Q4 2021 to 34.42% in Q2 2022 over the past five years.
- On a year-over-year basis, EBITDA Margin has declined for three consecutive quarters, with an average year-over-year change of -2.63 percentage points over the last eight quarters.
- Peak year-over-year performance for EBITDA Margin in the last five years was a gain of 166.41 percentage points in Q2 2022, against a drop of 34.74 percentage points in Q2 2026 at the low end.
- Per Business Quant, the preceding three quarters came in at -8.16% (Q1 2026), -14.29% (Q4 2025) and 8.11% (Q3 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 655.56 Bn | 574.09 Bn | 17.26 Bn | 35.95% |
| 2 | AbbVie | 470.94 Bn | 444.10 Bn | 12.70 Bn | 49.01% |
| 3 | Merck | 367.14 Bn | 321.57 Bn | 12.21 Bn | 6.02% |
| 4 | Novartis Ag | 280.33 Bn | 236.20 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 257.78 Bn | 231.34 Bn | 12.86 Bn | 33.11% |
| 6 | Amgen | 226.04 Bn | 181.44 Bn | 7.24 Bn | 46.01% |
| 7 | Gilead Sciences | 188.89 Bn | 163.01 Bn | 6.22 Bn | -124.26% |
| 8 | Pfizer | 163.75 Bn | 110.70 Bn | 10.94 Bn | 39.16% |
| 9 | Vertex Pharmaceuticals | 133.68 Bn | 105.69 Bn | 2.84 Bn | 39.10% |
| 10 | Akebia Therapeutics | 241.85 Mn | -427.63 Mn | 38.70 Mn | -11.69% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -11.69% |
| Mar 31, 2026 | -8.16% |
| Dec 31, 2025 | -14.29% |
| Sep 30, 2025 | 8.11% |
| Jun 30, 2025 | 23.06% |
| Mar 31, 2025 | 24.12% |
| Dec 31, 2024 | -10.67% |
| Sep 30, 2024 | -8.39% |
| Jun 30, 2024 | 1.55% |
| Mar 31, 2024 | -17.05% |
| Dec 31, 2023 | 19.18% |
| Sep 30, 2023 | -8.66% |
| Jun 30, 2023 | 0.71% |
| Mar 31, 2023 | -40.46% |
| Dec 31, 2022 | 8.16% |
| Sep 30, 2022 | -84.15% |
| Jun 30, 2022 | 34.42% |
| Mar 31, 2022 | -81.29% |
| Dec 31, 2021 | -96.89% |
| Sep 30, 2021 | -93.14% |
API Access
Akebia Therapeutics EBITDA Margin API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=ebitda-margin&ticker=AKBA&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "ebitda-margin", "ticker": "AKBA", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=ebitda-margin&ticker=AKBA&period=max&api_key=YOUR_API_KEY");
const data = await res.json();